Vázquez MJC, Archundia GA, Aceves CJL, Díaz QG, Laue NL

Language: Spanish
References: 17
Page: 15-18
PDF size: 51.75 Kb.

ABSTRACT

Background: Pulmonary hypertension crisis is the principal complication in patients with cardiac surgery for congenital cardiopathy. Method: This is a comparative, observational and retrospective study of the experience in “Centro Médico Nacional 20 de Noviembre”, ISSSTE, with the use of nitric oxide and milrinone for the decrease of pulmonary hypertension crisis in surgical patients of ventricular septal and atrioventricular septal defects with pulmonary hypertension between May 2000 and October 2002. We included 30 patients, 15 treated with nitric oxide and 15 with milrinone. We analyzed age, sex, diagnosis, preoperatory and postoperatory pulmonary hypertension, intubation days, lenght of stay and days in the ICU, number of pulmonary hypertension crisis, treatment nitric oxide or milrinone and mortality. Results: Both groups were similar except that the nitric oxide group had less pulmonary hypertension crisis, when compared with the milrinone group. Conclusion: In our experience the nitric oxide was more effective than milrinone for the disminishment of pulmonary hypertension postoperatory crisis.

REFERENCES

1. Knott-Craig CJ. Ventricular septal defect. In: Kaiser LR, Kron IL, Spray TL. Mastery of cardiothoracic surgery. Philadelphia, PA: Lippincott-Raven Publishers, 1998; 688-689.

2. Chatterjee KM, DeMarco T, Alpert JS. Pulmonary hypertension: Diagnosis and management. Arch Intern Med 2002; 162: 1925-1933.

3. Tuder RM, Lee SD, Cool CC. Histopathology of pulmonary hypertension. Chest 1998; 114: 1-6.

4. Hoffman JI, Rudolph AM, Heymann MA. Pulmonary vascular disease with congenital heart lesions: Pathologics features and causes. Circulation 1981; 64: 873-877.

5. Prielipp RC, Macgregor DA, Butterworth JF. Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically III patients. Chest 1996; 109: 1291-1301.

6. Bailey JM, Levy JH, Kikura M. Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. Anestesiology 1994; 81: 616-622.

7. Butterworth JB, Hines RL, Royster RL. A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. Anesth Analg l995; 81: 783-792.

8. Skimming JW, Banner MJ, Spalding HK, Jaeger MJ, Burchfield DJ, Davenport PW. Nitric oxide inhalation increase alveolar gas exchange by decreasing deadspace volume. Crit Care Med 2001; 29: 1195-1200.

9. Cooper CJ, Lanndzberg MJ, Anderson TJ. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation 1996; 93: 266-270.

10. Barts RJ. Pharmacologically induced pulmonary vasodilatation in children and young adult with hypertension pulmonary. Chest 1996; 89: 497-501.

11. Lindberg L, Olsson AK, Jonmarker C. How common is severe pulmonary hypertension after pediatric cardiac surgery? J Thoracic Cardiovasc Surg 2002; 123: 1155-1163.

12. Hopkins RA, Bull C, Haworth SG, De Leval MR, Stark J. Pulmonary hypertensive crisis following surgery for congenital heart defects in young children. Eur J Cardiothorac Surg 1991; 5: 628-634.

13. Miller OI, Fonf TS, Keech A, Pigott BN, Bellar E, Celermajer DS. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital surgery: a randomized double-blind study. Lancet 2000; 356: 1464-1469.

14. Bigatello LM, Hurford WE. Inhaled nitric oxide and pulmonary vascular resistance. Crit Care Med 1999; 27: 687-690.

15. Deb B, Bradford K, Pearl RG. Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension. Crit Care Med 2000; 28: 795-798.

16. Fullerton DA, Jaggers J, Wollmering MM, Piedalve F, Gover FL, McIntyre RC. Variable response to inhaled nitric oxide after cardiac surgery. Ann Thorac Surg 1997; 63: 1251-1256.

17. Roberts JD, Fineman JR, Morin FC. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997; 336: 605-610.